Adverse impact of delay of platelet recovery after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma and multiple myeloma.

[1]  S. Iida,et al.  Improved survival of multiple myeloma patients treated with autologous transplantation in the modern era of new medicine , 2021, Cancer science.

[2]  S. Fujiwara,et al.  Factors that predict delayed platelet recovery after autologous stem cell transplantation for lymphoma or myeloma , 2020, Annals of Hematology.

[3]  C. Compher,et al.  Nutrition-Related Outcomes for Autologous Stem Cell Transplantation Patients. , 2019, Clinical lymphoma, myeloma & leukemia.

[4]  J. Vose,et al.  Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation: A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT , 2019, JAMA oncology.

[5]  N. Geller,et al.  Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  G. Morgan,et al.  Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial , 2019, The Lancet. Oncology.

[7]  N. Nicolay,et al.  The current understanding of mesenchymal stem cells as potential attenuators of chemotherapy‐induced toxicity , 2018, International journal of cancer.

[8]  K. Vanderkerken,et al.  Mesenchymal stem cells in multiple myeloma: a therapeutical tool or target? , 2018, Leukemia.

[9]  H. Nakasone,et al.  Delayed platelet recovery after allogeneic hematopoietic stem cell transplantation: Association with chronic graft‐versus‐host disease and survival outcome , 2018, Hematological oncology.

[10]  H. Goldschmidt,et al.  From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives , 2017, Haematologica.

[11]  Sin-Ho Jung,et al.  Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Fujiwara,et al.  Retrospective evaluation of the MEAM regimen as a conditioning regimen before autologous peripheral blood stem cell transplantation for lymphoma in two centers with different dosing schedules of melphalan , 2016, Annals of Hematology.

[13]  T. Pabst,et al.  Delayed Haematological recovery after autologous stem cell transplantation is associated with favourable outcome in acute myeloid leukaemia , 2015, British journal of haematology.

[14]  Yu Wang,et al.  Association between an impaired bone marrow vascular microenvironment and prolonged isolated thrombocytopenia after allogeneic hematopoietic stem cell transplantation. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  M. Greenwood,et al.  Factors predicting haematopoietic recovery in patients undergoing autologous transplantation: 11-year experience from a single centre , 2014, Annals of Hematology.

[16]  Yan-rong Liu,et al.  Association of an impaired bone marrow microenvironment with secondary poor graft function after allogeneic hematopoietic stem cell transplantation. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[17]  L. Lagneaux,et al.  Evidences of Early Senescence in Multiple Myeloma Bone Marrow Mesenchymal Stromal Cells , 2013, PloS one.

[18]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[19]  K. Owzar,et al.  Lenalidomide after stem-cell transplantation for multiple myeloma. , 2012, The New England journal of medicine.

[20]  A. Nademanee,et al.  Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[21]  C. Brunstein,et al.  Delayed platelet recovery after allogeneic transplantation: a predictor of increased treatment-related mortality and poorer survival , 2011, Bone Marrow Transplantation.

[22]  M. Dimopoulos,et al.  Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. , 2011, Blood.

[23]  C. Dinarello,et al.  Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. , 2011, Blood.

[24]  P. Atadja,et al.  IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms. , 2010, Blood.

[25]  K. Akashi,et al.  Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group , 2010, Bone Marrow Transplantation.

[26]  D. Kaplan,et al.  Bone Marrow Osteoblastic Niche: A New Model to Study Physiological Regulation of Megakaryopoiesis , 2009, PloS one.

[27]  M. Kandefer-Szerszeń,et al.  Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells , 2008, Archivum Immunologiae et Therapiae Experimentalis.

[28]  K. Kawa,et al.  Unification of Hematopoietic Stem Cell Transplantation Registries in Japan and Establishment of the TRUMP System , 2007, International journal of hematology.

[29]  K. Bradstock,et al.  Failure to achieve a threshold dose of CD34+CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation , 2007, Bone Marrow Transplantation.

[30]  J. Armitage.  How I treat patients with diffuse large B-cell lymphoma. , 2007, Blood.

[31]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  G. Roodman,et al.  The role of immune cells and inflammatory cytokines in Paget's disease and multiple myeloma , 2005, Immunological reviews.

[33]  J. Crowley,et al.  International staging system for multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  M. Skinner,et al.  Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis , 2005, Bone Marrow Transplantation.

[35]  K. Podar,et al.  The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. , 2005, Blood.

[36]  Santhosh K. P. Kumar,et al.  Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy , 2004, Bone Marrow Transplantation.

[37]  Yulia Nefedova,et al.  Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. , 2004, Blood.

[38]  F. Zhan,et al.  The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. , 2003, The New England journal of medicine.

[39]  P. Varosy,et al.  High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[40]  Y. Kagami,et al.  Pilot Phase I/II Study of New Salvage Therapy (CHASE) for Refractory or Relapsed Malignant Lymphoma , 2003, International journal of hematology.

[41]  M. Angelopoulou,et al.  Cotransplantation of human mesenchymal stem cells enhances human myelopoiesis and megakaryocytopoiesis in NOD/SCID mice. , 2003, Experimental hematology.

[42]  M. Bhatia,et al.  Number of viable CD34+ cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation , 2002, Bone Marrow Transplantation.

[43]  P. Pedrazzoli,et al.  Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  S. Gerson,et al.  Phenotypic and functional comparison of cultures of marrow‐derived mesenchymal stem cells (MSCs) and stromal cells , 1998, Journal of cellular physiology.

[45]  R. Storb,et al.  Factors that influence collection and engraftment of autologous peripheral-blood stem cells. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  B. Barlogie,et al.  Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. , 1995, Blood.

[47]  A. Hirao,et al.  Effectiveness of high‐dose MCNU therapy and hematopoietic stem cell autografts treatment of childhood acute leukemia/lymphoma with high‐risk features , 1991, Cancer.

[48]  J. Armitage,et al.  High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. , 1987, The New England journal of medicine.

[49]  M Tubiana,et al.  Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.